NEW YORK, November 4, 2017 /PRNewswire/ --
• According to the Foundation for Women´s Cancer, every five minutes awoman will receive a gynecologic cancer diagnosis of cervical, ovarian, endometrial/uterine, or vaginal cancer
• PharmaMar is heavily involved in the investigation of three women's cancers (ovarian cancer, breast cancer and endometrial cancer)
(Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )
According to the Foundation for Women´s Cancer, every five minutes a woman will receive a gynecologic cancer diagnosis of cervical, ovarian, endometrial/uterine, or vaginal cancer. More than 107,470 women with a gynecologic cancer will be diagnosed this year and about 31,600 will die from these cancers in 2017.
PharmaMar is heavily involved in the investigation of three women's cancers (ovarian cancer, breast cancer and endometrial cancer) and is currently awaiting data, expected early in 2018, for its pivotal Phase III trial, CORAIL, in platinum relapsed ovarian cancer with Zepsyre®. The Company is also planning on starting registrational trials, with the same molecule Zepsyre® in both BRCA2 mutated breast cancer and second line endometrial cancer during 2018.
Pascal Besman, Chief Operating Officer of PharmaMar USA, said "it is a wonderful opportunity for us to partner with the 'National Race to End Women's Cancer' given their tremendous reach in the entire women's cancer community of patients, caregivers, physicians, advocates and others, and given our extensive clinical trials for Zepsyre in three of these cancers. I am honored to represent PharmaMar as a proud participant in this important event."
Karen Carlson, Executive Director of the Foundation for Women's Cancer, said "we're very excited and appreciative to have PharmaMar join the movement by sponsoring the 8th National Race to End Women's Cancer. We look forward to building upon our new partnership as we strive to increase public awareness of gynecologic cancer risk awareness, prevention, early detection and optimal treatment."
About PharmaMar Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS® in Europe and has other clinical-stage programs under development for several types of solid and hematological cancers, Zepsyre® (lurbinectedin - PM1183), plitidepsin, PM184 and PM14. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium, Austria and the United States. PharmaMar fully owns other companies: GENOMICA, a leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at http://www.pharmamar.com .
About the Foundation for Women's Cancer The Foundation for Women's Cancer is dedicated to increasing public awareness of gynecologic cancer risk awareness, prevention, early detection and optimal treatment. The official foundation of the Society of Gynecologic Oncology, the Foundation for Women's Cancer is a nonprofit organization that provides funding for gynecologic cancer research and training, as well as educational programs and resources. The FWC has raised more than $50 million in areas such as research, awareness, education, and outreach.
Disclaimer This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.
Investor Relations: Phone: +34-9144-44500
Or please visit our website at http://www.pharmamar.com
https://twitter.com/phrmmar https://es-la.facebook.com/PharmaMarES/ https://www.linkedin.com/company/pharmamar https://www.instagram.com/pharmamar/ https://www.youtube.com/c/Pharmamar_official
Alfonso Ortín - Communications Director firstname.lastname@example.org Mobile: +34-6094-93127 Paula Fernández - Media Relations Manager email@example.com Mobile: +34-6387-96215
Subscribe to our Free Newsletters!
A patient's struggle with Issacs' syndrome with no cure. Also known as neuromyotonia it is a rare ...
Inguinal hernia surgery is a procedure to repair a weak spot or defect in the lower wall of the ...
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...View All